A carregar...
Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma
The discovery of the ubiquitin–proteasome pathway first, and the proteasome inhibitors thereafter were not made in the hope of improving the treatment of malignant diseases. However, bortezomib, the first in class proteasome inhibitor introduced in the clinical practice has contributed to improve th...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3573435/ https://ncbi.nlm.nih.gov/pubmed/23556118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620711432020 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|